Top

Published in:

01-07-2009 | Original Article

Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas

Authors: Ali Ayhan, Guldeniz Aksan, Murat Gultekin, Sertac Esin, Cigdem Himmetoglu, Polat Dursun, Alp Usubutun, Kunter Yuce

Published in: Archives of Gynecology and Obstetrics | Issue 1/2009

Abstract

Objective

To analyze prognostic factors, the role of lymphadenectomy and postoperative adjuvant treatments in patients with uterine leiomyosarcomas (LMS).

Study design

Sixty-three patients with uterine LMS are retrospectively analyzed with respect to both DFS and OS.

Results

Multivariate DFS analysis revealed percentage necrosis to be the unique factor to be significant (median DFS was 3.31 years for <25% necrosis and 0.78 for >25% necrosis). Multivariate analysis revealed the mitotic counts to be the unique significant factor affecting the OS (median OS was 7.20 and 1.73 years, respectively, for patients with mitotic counts of 1–5 and >6; respectively). Median DFS was 2.51 years for patients who had undergone lymphadenectomy and 2.36 years for remaining who did not have a lymphadenectomy procedure (P = 0.4). With respect to OS, median values were 2.44 and 3.16 years, respectively (P = 0.7). Number of the resected lymph nodes was also not significant for both OS and DFS.

Conclusions

Mitotic counts and percentage necrosis have significant effects on OS and DFS; respectively. Neither the performance nor the extent of lymphadenectomy has an effect on patient survival.

Harlow BL, Weis NS, Lofton S (1986) The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 76:399–402PubMed

Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, Fuller AF Jr (1993) Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol 50(1):105–109. doi:10.1006/gyno.1993.1172 PubMedCrossRef

El Husseiny G, Al Bareedy N, Mourad WA et al (2002) Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol 25:256–260. doi:10.1097/00000421-200206000-00010 CCTPubMedCrossRef

Nordal RR, Kristensen GB, Kaern J et al (1995) The prognostic significance of stage, tumour size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 34:797–802. doi:10.3109/02841869509127189 PubMedCrossRef

Bell SW, Kempson RL, Hendrickson MR (1994) Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 18(6):535–558. doi:10.1097/00000478-199406000-00001 PubMedCrossRef

Benedet JL, Bender H, Jones HIII et al (2002) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 70:209–262

Evans HL, Chawla SP, Simpson C, Finn KP (1988) Smooth muscle neoplasm of the uterus other than ordinary leiomyoma: a study of 46 cases, with emphasis on diagnostic criteria and prognostic factor. Cancer 62:2239–2247. doi:10.1002/1097-0142(19881115)62:10<2239::AID-CNCR2820621028>3.0.CO;2-YPubMedCrossRef

Vardi JR, Tovell HMM (1980) Leiomyosarcoma of the uterus: a clinicopathologic study. Obstet Gynecol 56:428–434PubMed

Blom R, Guerrieri C, Stal O, Malmstrom H, Simonsen E (1998) Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 68:54–61. doi:10.1006/gyno.1997.4889 PubMedCrossRef

10.

Kahanpaa KV, Wahlstrom T, Grohn P et al (1986) Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 67:417–424PubMed

11.

Marchese MJ, Liskow AS, Crum CP et al (1984) Uterine sarcomas: a clinicopathologic study, 1965–1981. Gynecol Oncol 18:299–312. doi:10.1016/0090-8258(84)90041-6 PubMedCrossRef

12.

Larson B, Silfversward C, Nilsson B, Petterson F (1990) Prognostic factors in uterine leiomyosarcoma: a clinicopathologic study of 143 cases. The Radiumhemmet series, 1936–1981. Acta Oncol 29:185–191. doi:10.3109/02841869009126543 PubMedCrossRef

13.

Hart WR, Billman JK Jr (1978) A reassessment of uterine neoplasm originally diagnosed as leiomyosarcomas. Cancer 41:1902–1910. doi:10.1002/1097-0142(197805)41:5<1902::AID-CNCR2820410535>3.0.CO;2-KPubMedCrossRef

14.

Mayerhofer K, Obermair A, Windbichler G et al (1999) Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 74:196–201. doi:10.1006/gyno.1999.5436 PubMedCrossRef

15.

Pautier P, Genmestie C, Rey A et al (2000) Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88:1425–1431. doi:10.1002/(SICI)1097-0142(20000315)88:6<1425::AID-CNCR21>3.0.CO;2-3PubMedCrossRef

16.

Layfield LJ, Liu K, Dodge R, Barsky SH (2000) Uterine smooth muscle tumor. Utility of classification by proliferation, ploidy and prognostic markers versus traditional histopathology. Arch Pathol Lab Med 124(2):221–227PubMed

17.

Kattan MW, Leung DH, Brennan MF (2002) Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20:791–796. doi:10.1200/JCO.20.3.791 PubMedCrossRef

18.

Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, Gostout BS (2003) Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89(3):460–469. doi:10.1016/S0090-8258(03)00137-9 PubMedCrossRef

19.

Wu TI, Chang TC, Hsueh S, Hsu KH, Chou HH, Huang HJ, Lai CH (2006) Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol 100(1):166–172. doi:10.1016/j.ygyno.2005.08.010 PubMedCrossRef

20.

Bodner K, Bodner-Adler B, Kimberger O et al (2003) Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study. J Reprod Med 48:95–100PubMed

21.

Hsieh CH, Lin H, Huang CC et al (2003) Leiomyosarcoma of the uterus: a clinicopathologic study of 21 cases. Acta Obstet Gynecol Scand 82:74–81. doi:10.1034/j.1600-0412.2003.820114.x PubMedCrossRef

22.

Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS (2003) Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 91(1):209–212. doi:10.1016/S0090-8258(03)00478-5 PubMedCrossRef

23.

Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A (2004) The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General Hospital. Gynecol Oncol 92(2):648–652. doi:10.1016/j.ygyno.2003.10.044 PubMedCrossRef

24.

Moinfar F, Azodi M, Tavassoli FA (2007) Uterine sarcomas. Pathology 39(1):55–71. doi:10.1080/00313020601136146 PubMedCrossRef

25.

Major FJ, Blessing JA, Silverberg SG et al (1993) Prognostic factors in early stage uterine sarcoma. Cancer 71:1902–1909

26.

Dinh TV, Woodruff JD (1982) Leiomyosarcoma of the uterus. Am J Obstet Gynecol 144(7):817–823PubMed

27.

Chen SS (1989) Propensity of retroperitoneal lymph node metastasis in patients with stage I sarcoma of the uterus. Gynecol Oncol 32:215–217. doi:10.1016/S0090-8258(89)80035-6 PubMedCrossRef

28.

Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, Bazzurini L, Arisio R, Romagnolo C, Cristofani R (1996) Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 62:25–32. doi:10.1006/gyno.1996.0185 PubMedCrossRef

29.

Gard GB, Mulvany NJ, Quinn MA (1999) Management of uterine leiomyosarcoma in Australia. Aust N Z J Obstet Gynaecol 39(1):93–98. doi:10.1111/j.1479-828X.1999.tb03039.x PubMedCrossRef

30.

Leibsohn D, d’Ablaing G, Mishrll DR Jr, Schlaerth JB (1990) Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 162:968–974PubMed

31.

Kapp DS, Shin JY, Chan JK (2008) Prognostic factors and survival in 1,396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112(4):820–830. doi:10.1002/cncr.23245 PubMedCrossRef

Title: Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas
Authors: Ali Ayhan
Guldeniz Aksan
Murat Gultekin
Sertac Esin
Cigdem Himmetoglu
Polat Dursun
Alp Usubutun
Kunter Yuce
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 1/2009
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-008-0876-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas

Abstract

Objective

Study design

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Study design

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Diagnosis and laparoscopic management of 11 consecutive cases of cornual ectopic pregnancy

Prognostic significance of molecular classification of breast invasive ductal carcinoma

Prophylactic bilateral oophorectomy during vaginal hysterectomy for benign pathology

Neonatal outcome in preterm deliveries between 23 and 27 weeks’ gestation with and without preterm premature rupture of membranes

Comparative efficacy and safety of vaginal misoprostol versus dinoprostone vaginal insert in labor induction at term: a randomized trial

Multiple vaginal mullerian cysts: a case report and review of literature